$2.56
12.33%
Nasdaq, Oct 01, 04:26 pm EDT. Closed.
ISIN
US3724461047
Symbol
GNPX

Genprex, Inc. Stock price

$2.56
-0.99 27.89% 1M
-32.20 92.64% 6M
-35.94 93.35% YTD
-192.14 98.69% 1Y
-16,457.84 99.98% 3Y
-118,797.44 100.00% 5Y
-206,797.44 100.00% 10Y
-206,797.44 100.00% 20Y
Nasdaq, Closing price Thu, Oct 01 2026
-0.36 12.33%
ISIN
US3724461047
Symbol
GNPX
Industry

Is Genprex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.1m
Enterprise Value
$-13.1m
Net debt
positive
Cash
$15.2m
Shares outstanding
510.0k
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
0.8 | 0.8
P/B
0.1
Financial Health
Equity Ratio
78.4%
Return on Equity
-
ROCE
-107.1%
ROIC
-
Debt/Equity
0.0
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-15.8m
Net Income
$-16.5m
Free Cash Flow | ex SBC
$-15.6m | $-15.4m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
8.5%
Net Income
6.0%
Free Cash Flow
-10.5%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-34.9
FCF per Share
$-30.5
Short interest
10.1%
Employees
13
Rev per Employee
-

Genprex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Genprex, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Genprex, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Genprex, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.02 6.02
10% 10%
-
- Research and Development Expense 9.82 9.82
8% 8%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -16 -16
8% 8%
-
Net Profit -17 -17
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Genprex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genprex, Inc. Stock News

Neutral
PRNewsWire
●
about one month ago
Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials AUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered int...
Neutral
PRNewsWire
●
about 2 months ago
Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, t...
Neutral
PRNewsWire
●
3 months ago
Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Canadian Intellectual Property Office (C...
More Genprex, Inc. News

Company Profile

Genprex, Inc. is a clinical stage gene therapy company, which engages in the development of novel proprietary technology platform for the treatment of cancer. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Head office United States
CEO Mr. Confer
Employees 13
Founded 2009
Website www.genprex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today